IBIO, INC. Debt Securities, Available-for-sale, Amortized Cost
IBIO, INC. (IBIO) had Debt Securities, Available-for-sale, Amortized Cost of $31.69 million as of 2026-06-30, per its 10-K filed 2026-08-28.
Financial Statements › Notes › Credit Losses › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-28
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $31.69M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $27.19M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $24.02M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $21.47M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $31.69M 10-K · filed 2026-08-28 |
| 2026-03-31 | $27.19M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $24.02M 10-Q · filed 2026-02-10 |
| 2025-09-30 | $21.47M 10-Q/A · filed 2025-11-17 |
| 2022-12-31 | $6.07M 10-Q/A · filed 2023-05-19 |
| 2022-09-30 | $7.79M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $11.03M 10-K · filed 2023-09-27 |
| 2022-03-31 | $14.94M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $18.23M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $19.46M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $19.60M 10-K · filed 2022-10-11 |
| 2021-03-31 | $19.33M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $16.41M 10-Q · filed 2021-02-16 |
| 2020-09-30 | $6.02M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |